BGM
RCUS icon

Burkehill Global Management’s Arcus Biosciences RCUS Stock Holding History

Burkehill Global Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Hold
50,000
– – 0.05% 159
2025
Q4 		$1.19M Buy
+50,000
New +$1.02M 0.08% 143

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Burkehill Global Management's RCUS Position: Q1 2026 in Review

Burkehill Global Management held its Arcus Biosciences (RCUS) position steady in Q1 2026 at 50,000 shares worth $1.08M. The position accounts for 0.05% of the portfolio, ranked #159.

Burkehill Global Management first reported a position in RCUS in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.19M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Burkehill Global Management held 50,000 shares of Arcus Biosciences worth $1.08M as of Q1 2026.
  • Burkehill Global Management left its Arcus Biosciences share count unchanged in Q1 2026.
  • Arcus Biosciences made up 0.05% of Burkehill Global Management's portfolio in Q1 2026, its #159 holding.
  • Burkehill Global Management first reported a position in Arcus Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Burkehill Global Management's Arcus Biosciences position peaked at $1.19M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.